Abstract
Relationship between biological responses and binding affinities at I1/I2/I3 imidazoline receptors of compounds with imidazoline, pyrroline or oxazoline moieties was studied by 2D-QSAR, 3D-QSAR and quantitative pharmacophore development approaches. Since the I1 imidazoline receptor is involved in central inhibition of sympathicus that produce hypotensive effect, the I2 receptor is allosteric modulator of monoamine oxidase B (MAO-B) and the I3 receptor regulates insulin secretion from pancreatic β-cells, design and synthesis of selective I1/I2/I3 imidazoline ligands are very important for the development of new effective therapeutic agents. New agonists and antagonists with high selectivity for I1/I2/I3 imidazoline receptor classes have been recently synthesized and examined. The present review will highlight the main chemical diversity and pharmacophore features of selective I1/I2/I3 imidazoline receptor ligands.
Keywords: I1-imidazoline receptors, I2-imidazoline receptors, I3-imidazoline receptors, hypotensive, enzymes, phenylethanolamine-Nmethyl, imidazoline, imidazole-4-acetic, agmatine, lipophilicity
Mini-Reviews in Medicinal Chemistry
Title:Pharmacophore Development and SAR Studies of Imidazoline Receptor Ligands
Volume: 12 Issue: 14
Author(s): Katarina Nikolic and Danica Agbaba
Affiliation:
Keywords: I1-imidazoline receptors, I2-imidazoline receptors, I3-imidazoline receptors, hypotensive, enzymes, phenylethanolamine-Nmethyl, imidazoline, imidazole-4-acetic, agmatine, lipophilicity
Abstract: Relationship between biological responses and binding affinities at I1/I2/I3 imidazoline receptors of compounds with imidazoline, pyrroline or oxazoline moieties was studied by 2D-QSAR, 3D-QSAR and quantitative pharmacophore development approaches. Since the I1 imidazoline receptor is involved in central inhibition of sympathicus that produce hypotensive effect, the I2 receptor is allosteric modulator of monoamine oxidase B (MAO-B) and the I3 receptor regulates insulin secretion from pancreatic β-cells, design and synthesis of selective I1/I2/I3 imidazoline ligands are very important for the development of new effective therapeutic agents. New agonists and antagonists with high selectivity for I1/I2/I3 imidazoline receptor classes have been recently synthesized and examined. The present review will highlight the main chemical diversity and pharmacophore features of selective I1/I2/I3 imidazoline receptor ligands.
Export Options
About this article
Cite this article as:
Nikolic Katarina and Agbaba Danica, Pharmacophore Development and SAR Studies of Imidazoline Receptor Ligands, Mini-Reviews in Medicinal Chemistry 2012; 12 (14) . https://dx.doi.org/10.2174/138955712803832636
DOI https://dx.doi.org/10.2174/138955712803832636 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chemistry and Pharmacology of Angiotensin-Converting Enzyme Inhibitors
Current Pharmaceutical Design Stable Angina Pectoris: Current Medical Treatment
Current Pharmaceutical Design Molecular Mechanisms of Biological Activity of Oleanolic Acid - A Source of Inspiration for A New Drugs Design
Mini-Reviews in Organic Chemistry Serum Sickness Reaction to Rituximab with Positive Immediate Intradermal Skin Test: A Case Report
New Emirates Medical Journal Drug Reinforcement in a Rat Model of Attention Deficit/Hyperactivity Disorder – The Spontaneously Hypertensive Rat (SHR)
Current Drug Abuse Reviews Scopolamine and Depression: A Role for Muscarinic Antagonism?
CNS & Neurological Disorders - Drug Targets Peroxisome Proliferator-Activated Receptor-γ in Vascular Biology
Cardiovascular & Hematological Disorders-Drug Targets An Overview of Phytochemical and Pharmacological Profile of <i>Morus alba</i> Linn
Current Bioactive Compounds Gender Differences in Autonomic Control of the Cardiovascular System
Current Pharmaceutical Design Controversies in Glaucoma: Current Medical Treatment and Drug Development
Current Pharmaceutical Design α<sub>2</sub> Adrenoceptor: a Target for Neuropathic Pain Treatment
Mini-Reviews in Medicinal Chemistry Usefulness of Magnetic Resonance Imaging in Cardiac and Enovascular Intervention
Current Medical Imaging Combination of Therapeutic Hypothermia and Other Neuroprotective Strategies after An Ischemic Cerebral Insult
Current Neuropharmacology Chemical Intuition in Drug Design and Discovery
Current Topics in Medicinal Chemistry Drugs for AIDS
Mini-Reviews in Medicinal Chemistry Novel Antiinflammatory and Antiinfective Agents
Anti-Infective Agents in Medicinal Chemistry Vasopressin in Liver Disease – Should We Turn On or Off?
Current Clinical Pharmacology Quantitative Measurement of Some Physico-Chemical Parameters for the Medicinally Useful Natural Products
Letters in Drug Design & Discovery Targeting CFTR: How to Treat Cystic Fibrosis by CFTR-Repairing Therapies
Current Drug Targets The Diagnosis of Large Airway Pathology and the Role of Rigid Bronchoscopy
Current Respiratory Medicine Reviews